Cita APA

Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S. A., . . . Slamon, D. J. (2023). Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving frst-line ribociclib plus fulvestrant.

Citación estilo Chicago

Neven, P., P. A. Fasching, S. Chia, G. Jerusalem, M. De Laurentiis, S. A. Im, Luis de la Cruz Merino, y D. J. Slamon. Updated Overall Survival From the MONALEESA-3 Trial in Postmenopausal Women With HR+/HER2− Advanced Breast Cancer Receiving Frst-line Ribociclib Plus Fulvestrant. 2023.

Cita MLA

Neven, P., et al. Updated Overall Survival From the MONALEESA-3 Trial in Postmenopausal Women With HR+/HER2− Advanced Breast Cancer Receiving Frst-line Ribociclib Plus Fulvestrant. 2023.